TD Cowen Downgrades Aadi Bioscience Inc (AADI) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall Street eases as hopes for imminent Hormuz deal fade; Intel drops
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Nvidia and Wall Street giants plan $500B AI funding deal, FT reports
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil climbs 5% as Iran, US both demand compensation and Hormuz hopes fade
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Jefferies Downgrades Aadi Bioscience Inc (AADI) to Hold
August 21, 2024 3:47 PM EDTJefferies analyst Roger Song downgraded Aadi Bioscience Inc (NASDAQ: AADI) from Buy to Hold with a price target of $1.50 (from $11.00).
The analyst comments "We spoke w/ mgmt following IDMC demonstrated nab-sirolimus (mTOR) tumor agonostic pivotal in TSC1/TSC2 tumors was unlikely to... More
Aadi Bioscience (AADI) Provides PRECISION1 Trial and Corporate Updates
August 20, 2024 5:00 PM EDTAadi Bioscience, Inc. (NASDAQ: AADI) today announced it will halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. An analysis by the Independent Data Monitoring Committee demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval, the key goal of this Phase 2 study. The approximately 25 patients in PRECISION1 who are still benefiting from... More
